Grants & Projects per year
Fingerprint
Dive into the research topics where Thomas Jandl is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
GO43878: A Phase III, Open-label, Multicenter, Randomized Study Evaluating Glofitamab as a Single Agent Versus Investigator's Choice in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Gabig, T. (CoI), Jandl, T. (CoI), Lan, F. (CoI), Lee, C. (CoI), Liu, S. (CoI) & Schuster, M. (CoI)
06/26/26 → 08/29/26
Project: Research
-
GO44900: A Phase Ib Study Evaluating Safety Efficacy Pharmacokinetics & Pharmacodynamics of Glofitamab in Comination with Gemcitabine plus Oxaliplatin in Patients from Racial-Ethnic Minorities with Relapsed or Refractory Diffuse Cell Lympho
Gabig, T. (CoI), Jandl, T. (CoI), Lan, F. (CoI), Lee, C. (CoI), Liu, S. (CoI) & Schuster, M. (CoI)
05/1/26 → 01/28/27
Project: Research
-
Ntrust-1: A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects with Autoimmune Disease
Yao, Q. P. (PI), Gabig, T. (CoPI), Jandl, T. (CoPI), Lan, F. (CoPI), Lee, C. (CoPI), Liu, S. (CoPI) & Schuster, M. (CoPI)
05/16/25 → 08/19/26
Project: Research
-
Ntrust-2: A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy in Subjects with Immune-Mediated Diseases
Schuster, M. (PI), Gabig, T. (CoPI), Jandl, T. (CoPI), Lan, F. (CoPI), Lee, C. (CoPI) & Liu, S. (CoPI)
05/5/25 → 02/3/27
Project: Research
-
Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma
Schuster, M. (PI), Gabig, T. (CoPI), Jandl, T. (CoPI), Lan, F. (CoPI), Kiner-Strachan, B. (CoPI) & Salman, H. (CoPI)
08/23/17 → 05/3/24
Project: Research
-
Author Correction: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial (Nature Cancer, (2025), 6, 3, (528-539), 10.1038/s43018-025-00921-6)
on behalf of the ELM-2 Investigators, May 2025, In: Nature Cancer. 6, 5, p. 907 1 p.Research output: Contribution to journal › Comment/debate
Open Access1 Scopus citations -
Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial
ELM-2 Investigators, Mar 2025, In: Nature Cancer. 6, 3, p. 528-539 12 p.Research output: Contribution to journal › Article › peer-review
Open Access56 Scopus citations -
Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas
Soumerai, J. D., Diefenbach, C. S., Jagadeesh, D., Asch, A., Kumar, A., Tsai, M. L., Jandl, T. A., Lossos, I. S., Kenkre, V. P., Awan, F., Novotny, W., Huang, J., Miao, L., Rajagopalan, P., Ghalie, R. G. & Zelenetz, A. D., May 2024, In: British Journal of Haematology. 204, 5, p. 1762-1770 9 p.Research output: Contribution to journal › Article › peer-review
Open Access5 Scopus citations -
Convalescent Plasma for the Treatment of Severe COVID-19 Infection in Cancer Patients
The Mount Sinai Health System Convalescent Plasma Team, Nov 2020, In: Cancer Medicine. 9, 22, p. 8571-8578 8 p.Research output: Contribution to journal › Article › peer-review
Open Access30 Scopus citations -
Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease
Petro, C., González, P. A., Cheshenko, N., Jandl, T., Khajoueinejad, N., Bénard, A., Sengupta, M., Herold, B. C. & Jacobs, W. R., 2015, In: eLife. 2015, 4, p. 1-18 18 p., e06054.Research output: Contribution to journal › Article › peer-review
Open Access66 Scopus citations